bit.bio appoints Kathryn Corzo as Chief Working Officer

Cell coding firm bit.bio as we speak declares the important thing appointment of Kathryn Corzo as Chief Working Officer. She began within the position on 1 November 2021.

bit.bio appoints kathryn corzo as chief operating officer

From left: CEO Mark Kotter, CBO Paul Morrill, COO Kathryn Corzo, Co-Founder Florian Schuster, CMO Ramy Ibrahim. Picture Credit score: bit.bio

Corzo is a extremely regarded biotechnology govt with in depth expertise in early and late drug growth throughout a number of indications and platforms. Most lately she was companion at Takeda Ventures, Inc. and beforehand Head of Oncology Cell Remedy Improvement at Takeda Prescription drugs, the place she constructed capabilities and oversaw a leading edge oncology cell remedy portfolio together with CAR-T, CAR-NK, iPSC and gamma-delta platforms. She additionally served on Takeda’s R&D Administration Committee, was a member of Takeda’s Oncology Management Staff and served on the board of administrators for Maverick Therapeutics which was acquired by Takeda in March 2021.

Beforehand, Corzo was Sanofi Genzyme’s Vice President R&D Myeloma Head the place she led international registration applications to drug approvals within the US, EU and Japan. As well as, she held varied R&D management roles at Hoffmann-La-Roche, Roche Molecular Methods, Eli Lilly and Syndax, contributing to the preliminary approval of 6 revolutionary most cancers medicines and a number of indication expansions throughout the globe.

As COO, Corzo will sit on bit.bio’s govt crew and oversee all international operations. The appointment is vital for bit.bio as they develop their human cells for therapeutic purposes. She may even oversee all operations for the continued growth of the ioCells portfolio which gives human cells and illness fashions for analysis and drug discovery.

My ardour and life work is to ship transformative therapies for sufferers in want. Cell therapies maintain vital promise but R&D is extraordinarily costly and complicated. bit.bio has a novel platform expertise to handle many challenges of cell remedy growth by offering consistency, velocity and scale with its novel method to cell coding and reprogramming. As an rising biotech firm bit.bio has profound development potentialities. It’s excellent timing for me to affix and leverage my expertise to construct the corporate for fulfillment. ”


Kathryn Corzo, Chief Working Officer

Kathryn brings a wealth of related expertise and experience in addition to management. I welcome her into our firm and stay up for working together with her to ship on the promise of our expertise for sufferers. ”


Mark Kotter Founder, CEO

#bitbio #appoints #Kathryn #Corzo #Chief #Working #Officer